ESMO 2025
European Society for Medical Oncology Congress
Interviews and expert commentary from ESMO 2025 — study authors and key opinion leaders discuss the findings and their clinical implications.
Charles E Geyer MD; ESMO 2025: Antibody Drug Conjugate T-DXd Brings Longer Cancer-Free Survival for Patients with HER2-Positive Early Breast Cancer and Residual Invasive Disease
Charles E Geyer MD, at ESMO 2025, discusses DESTINY-Breast05 results, revealing trastuzumab deruxtecan (T-DXd) significantly improves disease-free survival for HER2-positive early breast cancer patients with residual invasive disease after neoadjuvant therapy. T-DXd outperformed trastuzumab emtansin
Jeanne Tie MD, ESMO Berlin: Liquid Biopsy Brings Chemo-free Option for Patients with Stage Three Colon Cancer
Some patients being treated for stage three colon cancer could avoid the use of chemotherapy and be spared toxicities such as neuropathy: according to a study in which ctDNA liquid biopsy monitoring f
Paul H Cottu MD PhD, ESMO Berlin: Chemo-Free Regimen with Neoadjuvant CDK 4/6 Inhibition plus Endocrine Therapy Benefits Patients with High-Risk ER+ HER2- Early Breast Cancer
Aan identifyable subset of patients with high-risk ER+ HER2- early breast cancer better off without chemotherapy
Li Zhang MD; ESMO 2025: Patients with EGFR-mutated Lung Cancer Progressing After Tyrosine Kinase Therapy Live Longer with Sacituzumab Tirumotecan Therapy
Antibody Drug Conjugate Prolongs Life in NSCLC refractory to EGFR TKI Therapy
Erwei Song MD PhD, ESMO Berlin: Antibody Drug Conjugate Trastuzumab Resetecan Brings Early Significant Progression Free Survival Benefit in Patients with Previously Treated HER2+ Advanced Breast Cancer
ADC beats SOC in previously treated Advanced Breast Cancer
Andrew Clamp MD, PhD, ESMO Berlin: Weekly Dose-Dose Chemotherapy Brings Big Survival Benefit for Patients with High-Risk Ovarian Cancer
An interview with: Andrew Clamp MD, PhD, Consultant Medical Oncologist, Christie Hospital, Manchester, UK BERLIN, Germany—An important therapeutic gain in terms of overall- and progression-free surviv
Nima Nabavizadeh MD; ESMO Berlin: Multi-Cancer Early Detection Test: PATHFINDER II study Finds Early Promise
multi-cancer early detection (MCED) test
Xiuning Le MD PhD; ESMO 2025: Sevabertinib Success for Patients with HER2-Mutated Non-Small Cell Lung Cancer in SOHO-01 Study
A new anti cancer drug sevabertinib, that targets mutated HER2, has proved effective in the SOHO-01 study among patients wiith HER2 mutated non small cell lung cancer. It has now been reported in the
ESMO 2025; Christof Vulsteke MD PhD: Perioperative Enfortumab Vedotin Therapy With Pembrolizumab Boosts Event-Free and Overall Survival in Platinum-Ineligible Patients with Muscle-Invasive Bladder Cancer: KEYNOTE-905 study
A big step forwards in the management of muscle invasive bladder cancer in which platinum cannot be used has been taken in the KEYNOTE-905 study of perioperative antibody drug conjugate thereapy with
Xichun Hu MD PhD; ESMO 2025: Antibody Drug Conjugate Trastuzumab Botidotin Outperforms Trastuzumab Emtansine in Patients with HER2-Positive Unresectable or Metastatic Breast Cancer
A Chinese ADC and a western ADC slugged it out at the 2025 ESMO held in Berlin.
Martin Wermke MD; ESMO 2025: Initial Therapy with Bi-Specific T-cell Engager Tarlatamab Promises Better Outcomes in Patients with Small Cell Lung Cancer
Tarlatamab, a bi-specific T-cell engager drug added to innitial immunochemotherapy brought encouraging initial survival outcomes in the DeLLphi-303 reported at the European Society for Medical Oncolog
John P. Crown MD MBA: ESMO 2025, Berlin: Adjuvant Ribociclib Brought Longer Freedom from Metastases for Patients with HR+/HER2- Early Breast Cancer: NATALEE Five Year Outcomes
John P. Crown MD MBA: ESMO 2025, Berlin: Adjuvant Ribociclib Brought Longer Freedom from Metastases for Patients with HR+/HER2- Early Breast Cancer: NATALEE Five Year Outcomes
Javier C Cortés MD PhD: ESMO 2025, Berlin: Initial Therapy with Sacituzumab Govitecan Improves Progression-Free Survival in Patients with Newly-Diagnosed Metastatic Triple Negative Breast Cancer—ASCENT-03 study
Javier Cortés tells his findings from ASCENT-03 as reported to ESMO 2025 in Berlin with antibody drug conjugate as initial therapy for TNBC in patients testing negative for PD-1/PD-L1
Trevor Leong MD: Operable Gastric or GE-Junction Adenocarcinoma: No Advantage from Neoadjuvant Radiotherapy
resectable-gastric-and-ge-junction adenocarcinoma-radiation-therapy-no-help
Domenica Lorusso MD PhD: Adding Early PD-1 Checkpoint Inhibition brings Big Reduction of Deaths for Patients with Newly Diagnosed Locally Advanced High-Risk Cervix Cancer
Domenica Lorusso MD PhD: Initial therapy with Pembrolizumab added to chemoradiotherapy boosts survival in high-risk locally advanced cervix cancer
James Larkin FRCP, PhD: CheckMate 067 Study 10-Year Data Show Advanced Melanoma Landscape Transformed by Combo Checkpoint Inhibitor Therapy
James Larkin FRCP, PhD talks about the big changes in survival prospects for patients with advanced and metastatic melanoma that have take place over the last 10 years thanks to combination checkpoint
Rebecca Dent MD: ESMO Previous Highlights: Neo-Adjuvant Therapy for Triple Negative Breast Cancer, Checkpoint Inhibition, AI, Cancer Vaccines, and More ……
Rebecca Dent surveys the most recent ESMO Annual Meeting to prepare our thoughts for the ESMO 2025 meeting
Bart Neyns MD PhD: Patients with Recurrent Glioblastoma Lived Markedly Longer in Phase 1 Study of Intracranial Autologous Myeloid Dendritic Cell Therapy
bart-neyns-md-phd-injectng-cells-into-cranial-cavity-for-recurrent-glioblastoma-long-survival